The Feasibility of Using the Ultravision™ System to Facilitate Low Impact Laparoscopic Surgery for the Treatment of Endometriosis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- Procedure Completed Without Change in Intra-abdominal Pressure
研究概览
简要总结
This is a prospective single arm study. The study will enroll 20 patients. Comparisons to prior clinical trials and published literature will be made to assess the relative significance of the study results.The study will enroll patients indicated for laparoscopic surgery to treat endometriosis. Patients must meet all inclusion/exclusion criteria.
There are five main study objectives:
- Demonstrate the feasibility of undertaking low impact laparoscopic surgery for endometriosis when using the Ultravision™ System.
- Assess the impact of Ultravision on visual field clarity.
- Determine the ability to complete the procedure while maintaining an abdominal pressure of < 10mmHg.
- Quantify the consumption of CO2.
- Collect data on additional clinical outcomes associated with the use of Ultravision and low impact surgery (i.e. end tidal CO2 levels (EtCO2), adverse events, cosmesis outcome, postoperative pain levels and pain medications).
详细描述
Background/Introduction: The Ultravision™ System is an FDA-cleared medical device that removes surgical smoke by means of electrostatic precipitation from the visual field during laparoscopic surgical procedures. "Surgical smoke" refers to the suspended particulate matter that is generated as a by-product of the combustion and other processes that are associated with the use of energy-based surgical instruments. Surgical smoke can obscure (partially or totally) the surgeon's view of the operative field and this has obvious safety implications for the patient. In the case of laparoscopic procedures, which are increasing in popularity, the smoke is retained within the "closed abdomen" and this, coupled with the CO2 pneumoperitoneum, presents additional challenges for the surgical team. The Ultravision™ System can therefore be considered an accessory to electrosurgical instruments to clear the surgical smoke generated during their use and as such will only be used when such devices are in use. The ability to operate at under "low impact" laparoscopic conditions has been shown by others to improve clinical outcomes by, for example, reducing post-surgical pain and with smaller incision sizes, improved cosmesis. For the purposes of this study "low impact" is defined as (1) a target pneumoperitoneal pressure of 10mm Hg; and (2) instead of 10mm and/or 12mm ports, the use of 3mm ports and one 5mm port. Using a standard insufflator, the combination of lower pneumoperitoneal pressure and smaller size ports creates visualization challenges for the surgeon due to the difficulty of preventing the buildup of surgical smoke within the abdomen. "Venting" or actively extracting the smoke through a trocar is known to be largely ineffective due to the narrow internal diameter of 3mm trocars, certainly unless the instrument is removed beforehand, which creates additional surgical challenges. Furthermore, operating under lower pressure can cause pneumoperitoneum to be lost upon venting of the smoke. The research question that is posed in this study is whether the Ultravision™ System, due to its unique mode of action which (unlike other smoke management approaches) provides smoke management without needing to extract or exchange CO2, provides effective visual field clearing, thereby facilitating low impact laparoscopic surgery when using a conventional insufflator. In addition, Ultravision™ does not require CO2 removal and replacement to achieve its intended use, thereby minimizing to the greatest extent possible patient CO2 exposure. CO2 is dry (effectively 0% relative humidity) and cold (typically 65F) and exposure is linked to postoperative pain and other adverse consequences such as patient cooling and tissue desiccation. Due its mode of action, Ultravision™ minimizes CO2 exposure to the patient. Laparoscopic surgery for the treatment of endometriosis is a common procedure for the removal of mild to moderate endometriosis. Diathermy is commonly used to remove the lesions which can be extensive, therefore this procedure presents an appropriate surgical procedure for this study. Assessments in terms of surgical field visualization, CO2 consumption, end tidal CO2, patient satisfaction for cosmesis, and postoperative pain will be conducted in order to determine if the Ultravision™ System is effective in enabling laparoscopic surgery under low impact laparoscopic conditions. Adverse event information will be reported. The study is an open label single arm study.
Study Purpose: There are five main study objectives:
- Demonstrate the feasibility of undertaking low impact laparoscopic surgery for endometriosis when using the Ultravision™ System.
- Assess the impact of Ultravision on visual field clarity.
- Determine the ability to complete the procedure while maintaining an abdominal pressure of < 10mmHg.
- Quantify the consumption of CO2.
- Collect data on additional clinical outcomes associated with the use of Ultravision and low impact surgery (i.e. end tidal CO2 levels (EtCO2), adverse events, cosmesis outcome, postoperative pain levels and pain medications).
Study Hypothesis: The primary hypothesis being tested in this study is that Ultravision facilitates the utilization of low impact laparoscopic surgery techniques whilst maintaining an adequate visual field throughout the procedure with low demand for CO2 replenishment to maintain pneumoperitoneal pressure. Study Population The study will enroll patients indicated for laparoscopic surgery to treat endometriosis. Patients must meet all inclusion/exclusion criteria.
Study Design: This is a prospective single arm study. The study will enroll 20 patients. Comparisons to prior clinical trials and published literature will be made to assess the relative significance of the study results.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
盲法说明
A sample size of 20 patients should provide a sufficient sample size for comparative analysis to prior clinical data relative to Ultravision and published peer reviewed clinical data on laparoscopy and low impact laparoscopy
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Subjects MUST meet all the following:
- •Is 18 years or older.
- •Provide written informed consent prior to trial procedures after studies indicate that the patient needs the prescribed procedure.
- •Agrees to attend all follow-up assessments.
- •Is indicated for laparoscopic surgery for the treatment of endometriosis.
- •Able to read and understand English.
排除标准
- •Subjects MUST not have any of the following:
- •Existing comorbidities that would contraindicate them for laparoscopic surgery.
- •Patient anatomy that is not compatible with the use of the Ionwand catheter i.e. abdominal wall thickness that exceeds the working length of the Ionwand catheter identified intraoperatively
- •Patient with a BMI > 50
- •Be pregnant
结局指标
主要结局
Procedure Completed Without Change in Intra-abdominal Pressure
时间窗: Intraoperative
The ability to complete the procedure without increasing pneumoperitoneum due to visualization. Any increase beyond 10mm Hg and the reason for change will be recorded.
Quality of Visualization Laparoscopic Field
时间窗: Intra-operative
The quality of visualization in the laparoscopic field of view will be assessed by the investigator using a Visual Analog Scale (VAS). The scale will rate the overall quality of visualization during the procedure on a scale numbered 0 to 100, in increments of 10, where 0 equals poor and 100 equals excellent.
次要结局
- Postoperative Abdominal Pain Assessment (Day 1-7)(Day 1-7 postoperative)
- Opioid/Opioid-containing Medication Taken Postoperatively for Pain(Day 1-7 postoperative)
- Postoperative Shoulder Pain Assessment (Day 1-7)(Day 1-7 postoperative)
- Cosmesis Outcome(A mean of 31 days (SD=2.8) after surgical procedure)
- Non-opioid Medication Taken Postoperatively for Pain(Day 1-7 postoperative)
研究者
David Levine
Director Minimally Invasive Gynecology
Mercy Research
